Medical Staff Pulse Newsletter

FDA Strengthens Warning for Montelukast

The U.S. Food and Drug Administration (FDA) is strengthening an existing warning for montelukast (Singulair and generics) in light of known side effects of serious behavior and mood-related changes.

For patients with asthma, the FDA recommends healthcare professionals consider the benefits and risks of mental health side effects before prescribing montelukast.

The FDA website has more information.